Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Catia Cilloniz & Antoni Torres. (2023) The pharmacokinetic evaluation of omadacycline (Oral Only Dosing Regimen) for the treatment of Community-Acquired Bacterial Pneumonia (CABP). Expert Opinion on Drug Metabolism & Toxicology 19:9, pages 569-576.
Read now
Read now
Changquan Fang, Limin Xu, Jiarong Tan, Hongyi Tan, Junhong Lin & Ziwen Zhao. (2022) Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Multiple Organ Failure: A Case Report. Infection and Drug Resistance 15, pages 5831-5838.
Read now
Read now
Teena Chopra, Avnish Sandhu, Nicolette Theriault, Joni Meehan & Glenn Tillotson. (2020) Omadacycline: A Therapeutic Review of use in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infections. Future Microbiology 15:14, pages 1319-1333.
Read now
Read now
Rodrigo M Burgos & Keith A Rodvold. (2019) Omadacycline: a novel aminomethylcycline. Infection and Drug Resistance 12, pages 1895-1915.
Read now
Read now
B Amalakuhan, KL Echevarria & MI Restrepo. (2017) Managing community acquired pneumonia in the elderly – the next generation of pharmacotherapy on the horizon. Expert Opinion on Pharmacotherapy 18:11, pages 1039-1048.
Read now
Read now
Gaoqi Xu, Xin Liu, Jiaqi Wang, Yuqing Mei, Dihong Yang, Chaoneng He, Like Zhong, Junfeng Zhu, Haiying Ding & Luo Fang. Evaluation of omadacycline regimens for community-acquired bacterial pneumonia patients infected with Staphylococcus Aureus by pharmacokinetic/pharmacodynamic analysis. Journal of Chemotherapy 0:0, pages 1-8.
Read now
Read now
Articles from other publishers (29)
Matteo Bassetti, Daniele R. Giacobbe, Laura Magnasco, Alberto Fantin, Antonio Vena & Nadia Castaldo. (2024) Antibiotic Strategies for Severe Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine 45:02, pages 187-199.
Crossref
Crossref
Chenlin Hu, Weiqun Wang, Jinhee Jo & Kevin W. Garey. (2024) Development and validation of LC-MS/MS for quantifying omadacycline from stool for gut microbiome studies. Journal of Chromatography B 1236, pages 124057.
Crossref
Crossref
Jinhee Jo, Chenlin Hu, Khurshida Begum, Weiqun Wang, Thanh M Le, Samantha Agyapong, Blake M Hanson, Hossaena Ayele, Chris Lancaster, M Jahangir Alam, Anne J Gonzales-Luna & Kevin W Garey. (2024) Fecal Pharmacokinetics and Gut Microbiome Effects of Oral Omadacycline Versus Vancomycin in Healthy Volunteers. The Journal of Infectious Diseases 229:1, pages 273-281.
Crossref
Crossref
William A. Bower, Yon Yu, Marissa K. Person, Corinne M. Parker, Jordan L. Kennedy, David Sue, Elisabeth M. Hesse, Rachel Cook, John Bradley, Jürgen B. Bulitta, Adolf W. Karchmer, Robert M. Ward, Shana Godfred Cato, Kevin Chatham Stephens & Katherine A. Hendricks. (2023) CDC Guidelines for the Prevention and Treatment of Anthrax, 2023. MMWR. Recommendations and Reports 72:6, pages 1-47.
Crossref
Crossref
Do Young Kim & Erin McElvania. (2023) Review of Novel Third-Generation Tetracyclines: Eravacycline, Omadacycline, and Sarecycline. Clinical Microbiology Newsletter 45:8, pages 61-67.
Crossref
Crossref
Richie Rashmin Bhandare, Benjamin E. Blass & Daniel J. Canney. 2023. Medicinal Chemistry of Chemotherapeutic Agents. Medicinal Chemistry of Chemotherapeutic Agents
115
133
.
Ashley R. Rizzo & Nader H. Moniri. (2022) Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use. BMC Infectious Diseases 22:1.
Crossref
Crossref
Ira M. Leviton & Maria Amodio-Groton. (2022) Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection. Clinical Drug Investigation 42:3, pages 193-197.
Crossref
Crossref
Noah Budi, Jared J. Godfrey, Nasia Safdar, Sanjay K. Shukla & Warren E. Rose. (2021) Omadacycline Compared to Vancomycin When Combined with Germinants To Disrupt the Life Cycle of Clostridioides difficile. Antimicrobial Agents and Chemotherapy 65:5.
Crossref
Crossref
Oliver A. Cornely, Thomas M. FileJr.Jr., Lynne Garrity-Ryan, Surya Chitra, Robert Noble & Paul C. McGovern. (2021) Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment. International Journal of Antimicrobial Agents 57:2, pages 106263.
Crossref
Crossref
Thomas L. Hunt, Evan Tzanis, Stephen Bai, Amy Manley, Surya Chitra & Paul C. McGovern. (2020) The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study. European Journal of Drug Metabolism and Pharmacokinetics 46:1, pages 85-92.
Crossref
Crossref
Monique R. Bidell, Manjunath (Amit) P. Pai & Thomas P. Lodise. (2020) Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class. Antibiotics 9:12, pages 905.
Crossref
Crossref
Steven J. Kovacs, Lillian Ting, Jens Praestgaard, Gangadhar Sunkara, Haiying Sun, Daniel S. Stein, S. Ken Tanaka & Stephen Villano. (2020) An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline. Antimicrobial Agents and Chemotherapy 64:11.
Crossref
Crossref
Keith A. Rodvold, Rodrigo M. Burgos, Xing Tan & Manjunath P. Pai. (2019) Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. Clinical Pharmacokinetics 59:4, pages 409-425.
Crossref
Crossref
George G. Zhanel, Jenine Esquivel, Sheryl Zelenitsky, Courtney K. Lawrence, Heather J. Adam, Alyssa Golden, Rachel Hink, Liam Berry, Frank Schweizer, Michael A. Zhanel, Denice Bay, Philippe R. S. Lagacé-Wiens, Andrew J. Walkty, Joseph P. LynchIIIIII & James A. Karlowsky. (2020) Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent. Drugs 80:3, pages 285-313.
Crossref
Crossref
Borje Darpo, Hongqi Xue, S. Ken Tanaka & Evan Tzanis. (2019) Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects. Antimicrobial Agents and Chemotherapy 63:10.
Crossref
Crossref
Richard R Watkins & Stan Deresinski. (2019) Omadacycline: A Novel Tetracycline Derivative With Oral and Intravenous Formulations. Clinical Infectious Diseases 69:5, pages 890-896.
Crossref
Crossref
Jason C Gallagher. (2019) Omadacycline: A Modernized Tetracycline. Clinical Infectious Diseases 69:Supplement_1, pages S1-S5.
Crossref
Crossref
Keith A Rodvold & Manjunath P Pai. (2019) Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. Clinical Infectious Diseases 69:Supplement_1, pages S16-S22.
Crossref
Crossref
Yvette N. Lamb & Katherine A. Lyseng-Williamson. (2019) Omadacycline in community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: a profile of its use. Drugs & Therapy Perspectives 35:7, pages 305-314.
Crossref
Crossref
John A. Dougherty, Allana J. Sucher, Elias B. Chahine & Katherine C. Shihadeh. (2018) Omadacycline: A New Tetracycline Antibiotic. Annals of Pharmacotherapy 53:5, pages 486-500.
Crossref
Crossref
J. Scott Overcash, Pouru Bhiwandi, Lynne Garrity-Ryan, Judith Steenbergen, Stephen Bai, Surya Chitra, Amy Manley & Evan Tzanis. (2019) Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study. Antimicrobial Agents and Chemotherapy 63:5.
Crossref
Crossref
Danial E. Baker. (2019) Omadacycline. Hospital Pharmacy 54:2, pages 80-87.
Crossref
Crossref
Ines B. Moura, Anthony M. Buckley, Duncan Ewin, Sharie Shearman, Emma Clark, Mark H. Wilcox & Caroline H. Chilton. (2019) Omadacycline Gut Microbiome Exposure Does Not Induce Clostridium difficile Proliferation or Toxin Production in a Model That Simulates the Proximal, Medial, and Distal Human Colon. Antimicrobial Agents and Chemotherapy 63:2.
Crossref
Crossref
Katie E. Barber, Alison M. Bell, Mary Joyce B. Wingler, Jamie L. Wagner & Kayla R. Stover. (2018) Omadacycline Enters the Ring: A New Antimicrobial Contender. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38:12, pages 1194-1204.
Crossref
Crossref
Jolene K. Berg, Evan Tzanis, Lynne Garrity-Ryan, Stephen Bai, Surya Chitra, Amy Manley & Stephen Villano. (2018) Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function. Antimicrobial Agents and Chemotherapy 62:2.
Crossref
Crossref
Mark H. Gotfried, Karolyn Horn, Lynne Garrity-Ryan, Stephen Villano, Evan Tzanis, Surya Chitra, Amy Manley, S. Ken Tanaka & Keith A. Rodvold. (2017) Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy 61:9.
Crossref
Crossref
Evan Tzanis, Amy Manley, Stephen Villano, S. Ken Tanaka, Stephen Bai & Evan Loh. (2016) Effect of Food on the Bioavailability of Omadacycline in Healthy Participants. The Journal of Clinical Pharmacology 57:3, pages 321-327.
Crossref
Crossref
Wen Lin, Jimmy Flarakos, Yancy Du, Wenyu Hu, Handan He, James Mangold, S. Ken Tanaka & Stephen Villano. (2017)
Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of
14
C-Omadacycline in Rats
. Antimicrobial Agents and Chemotherapy 61:1.
Crossref
Crossref